bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2021.
- In light of stronger than expected respiratory panels sales in Q4, full-year 2021 net sales are now expected to grow above 8% at constant exchange rates and scope of consolidation (previously: 4% to 7%) and contributive operating income before non-recurring items to be above €780 million (previously: above €700 million).
- As a reminder, this 2021 exceptional performance is not projectable beyond 2021.
Download the press release
- 196 KB